Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00721370 · ClinicalTrials.gov registry record · Phase 1
Near-Infrared Fluorescent Sentinel Lymph Node Mapping for Breast Cancer
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00721370 is a Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT00721370, a Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Sentinel lymph node (SLN) mapping is the standard of care for the surgical staging of breast cancer. We propose a method of SLN mapping based on the use of invisible near-infrared fluorescent light that has significant advantages for both patient and surgeon. The present study is a 6-patient pilot study designed to optimize clinical workflow with the new imaging system.
Interventions
- DEVICE NIR imaging system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00721370
The ClinicalTrials.gov registry entry for NCT00721370 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NIR imaging system is the first listed.
NCT00721370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00721370 about?
NCT00721370 is a clinical study titled "Near-Infrared Fluorescent Sentinel Lymph Node Mapping for Breast Cancer". Sentinel lymph node (SLN) mapping is the standard of care for the surgical staging of breast cancer. We propose a method of SLN mapping based on the use of invisible near-infrared fluorescent light that has significant advantages for both patient and surgeon. The present study is a 6-patient pilot s...
What is the current status of trial NCT00721370?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-07. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00721370?
The interventions under investigation include: NIR imaging system (DEVICE).
Who is sponsoring clinical trial NCT00721370?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.